GRI Bio (NASDAQ:GRI – Get Free Report) will likely be releasing its Q1 2025 earnings data before the market opens on Friday, May 9th. Analysts expect GRI Bio to post earnings of ($4.08) per share for the quarter.
GRI Bio Stock Performance
GRI stock opened at $1.95 on Friday. GRI Bio has a 52-week low of $1.10 and a 52-week high of $106.04. The firm has a market capitalization of $1.02 million, a price-to-earnings ratio of -0.17 and a beta of -1.72. The firm has a 50 day moving average price of $4.08 and a 200-day moving average price of $9.47.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of GRI Bio in a report on Monday, April 14th.
About GRI Bio
GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.
Further Reading
- Five stocks we like better than GRI Bio
- 5 Top Rated Dividend Stocks to Consider
- The Most Inspiring Small Businesses of 2025 [Survey]
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Microsoft Crushes Earnings, What’s Next for MSFT Stock?
- What Investors Need to Know to Beat the Market
- McDonald’s Insiders Sell Shares! Investors Should Do the Opposite
Receive News & Ratings for GRI Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRI Bio and related companies with MarketBeat.com's FREE daily email newsletter.
